Tofacitinib for polyarteritis nodosa: A tailored therapy

Annals of the Rheumatic Diseases

Volumn 75, Issue 12, 2016, Pages 2214-2216

  Rimar, Doron ^a   Alpert, Ayelet ^a   Starosvetsky, Elina ^a   Rosner, Itzhak ^a   Slobodin, Gleb ^a   Rozenbaum, Michael ^a   Kaly, Lisa ^a   Boulman, Nina ^a   Awisat, Abid ^a   Ginsberg, Shira ^a   Zilber, Karina ^a   Shen Orr, Shai S ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cytokines; Systemic vasculitis; Treatment

Indexed keywords

ADALIMUMAB; ADENOSINE DEAMINASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; JANUS KINASE 3 INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; POTASSIUM IODIDE; PREDNISONE; RITUXIMAB; STAT PROTEIN; STAT3 PROTEIN; TOFACITINIB; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; ARTHRITIS; BLOOD CULTURE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; ECHOCARDIOGRAPHY; GENE MUTATION; HUMAN; LETTER; LIVEDO RETICULARIS; MALE; PLASMAPHERESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REFRACTORY POLYARTERITIS NODOSA; REMISSION; RHEUMATOID ARTHRITIS; SEROLOGY; SIGNAL TRANSDUCTION; SKIN NODULE; TREATMENT RESPONSE; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FOLLOW UP; GENETICS; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NEEDLE BIOPSY; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOPSY, NEEDLE; COMPUTED TOMOGRAPHY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR TARGETED THERAPY; PIPERIDINES; POLYARTERITIS NODOSA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RECURRENCE; SEVERITY OF ILLNESS INDEX; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84984608890     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209330     Document Type: Letter

References (5)

1. Tanaka Y, Maeshima K, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 2):i70-4.
2. Gao W, McGarry T, Orr C, et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis 2016;75:311-15.
3. Danese S, Grisham MB, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016;310:G155-62.
4. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014;370:921-31.
5. Corbera-Bellalta M, Planas-Rigol E, Lozano E, et al. Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis 2016;75:1177-86.